Prof. Dr. med. Sven Mahner - PARP-Inhibitoren beim Eierstockkrebs - welcher, wann und wie lange from Oncoletter on Vimeo.
The combination of TAS-102 plus bevacizumab could be a new treatment option for patients with refractory metastatic colorectal cancer and could be a practice-changing development (cited in the Lancet Oncology)
Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Breast Cancer That Progressed on Endocrine Therapy
PRESS RELEASEDate Bern, December 12, 2019